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Abstract
Recent literature reports an increased incidence of venous thrombosis following thalidomide use in the treatment
of diseases with disease-related thrombotic risks such as malignancy, as well as concomitant use with
chemotherapy and/or systemic corticosteroids. We report a case of deep vein thrombosis (DVT) and pulmonary
embolism (PE) following thalidomide use in a patient with erythema nodosum leprosum (ENL) reaction who was
concurrently treated with prednisolone, as well as a review of relevant literature.
Background
The benefit of the immunomodulatory effects of thalido-
mide was discovered accidentally in 1965 when it was
given to patients with leprosy as a sedative to relieve their
suffering. Subsequently, researchers noticed an unexpected
clinical improvement in the signs and symptoms of ENL.
Since then, the off-label use of thalidomide has become
increasingly popular due to its effectiveness in the treat-
ment of a variety of malignant and non-malignant condi-
tions refractory to other treatments. Although common
adverse effects of thalidomide therapy are well-documen-
ted in literature since its introduction, some of the uncom-
mon risks associated with its use are still being discovered.
In the recent past, there has been an increased incidence
of adverse events being reported in patients treated with
thalidomide including thromboembolic complications
such as deep vein thrombosis (DVT) and pulmonary
embolism (PE). Many studies have reported thomboem-
bolic events with thalidomide when used in combination
with multi-drug chemotherapy regimens for the treatment
of multiple myeloma [1]. These thrombotic events have
also been reported in non malignant conditions treated
with thalidomide. A literature search shows few cases of
DVT in patients treated with thalidomide for ENL and so
far only two cases have been reported with concurrent
DVT and pulmonary embolism. [2,3]
Case presentation
A 60-year old man from Sri Lanka presented with a his-
tory of sudden onset breathlessness and right sided
pleuritic chest pain. 5 days before he had developed a
painful swelling of his right leg while he was being
treated in the hospital for recurrent episodes of ENL.
3 years ago he was diagnosed to have lepromatous
leprosy following a positive slit skin smear for mycobac-
terium leprae. He was commenced on World Health
Organization (WHO) multi-drug therapy (MDT) regi-
men for multi-bacilary (MB) leprosy, which was compli-
cated by type II lepra reaction (ENL) with right sided
panuveitis and treated with oral prednisolone 30 mg/day
with gradual tapering to 10 mg/day. He continued to
develop recurrent episodes of ENL reactions since the
completion of MDT-MB which was managed only with
prednisolone. 3 months before the current admission he
was started on a second course of MDT-MB treatment
for new skin nodules with a positive slit skin smear for
mycobacterium leprae. 3 weeks before he was com-
menced on thalidomide 100 mg twice daily in addition
to oral prednisolone of 15mg per day for refractory
ENL. He did not have recent major surgery, prolonged
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There was no history suggestive of past venous or arter-
ial thrombosis and tendency to develop thrombosis in
his family.
On examination he was dyspnoeic at rest without cen-
tral cyanosis. He had leonine facies and generalized
erythematous skin with multiple nodules. His right leg
was swollen with pitting ankle oedema (figure 1) while
having normal arterial pulses. His respiratory system
examination revealed a respiratory rate of 30 per minute
and signs of right lower zone pleural effusion. He had
tachycardia with a rate of 110 beats per minute, blood
pressure of 110/70 mm Hg and a normal jugular venous
pressure. Neurology revealed a glove and stocking sen-
sory peripheral neuropathy. There was no organomeg-
ally noted on abdominal examination.
During initial evaluation a venous doppler ultrasound
of the lower limb confirmed a deep vein thrombosis in
the right femoral vein. Subsequently a computed tomo-
graphy pulmonary angiography (CTPA) confirmed pul-
monary emboli in the right and left main pulmonary
arteries with right lower lobe lung collapse and a mild
pleural effusion (figure 2). His initial blood counts
showed a mild anaemia, a normal white cell and differ-
ential count and thrombocytopenia of 90k/mm
3 which
normalized following withdrawal of thalidomide. His
liver and renal function tests were within normal limits.
He was started on enoxaparin and warfarin concomi-
tantly and the target INR of 2.5 was achieved on day 7.
Thalidomide and anti leprosy therapy were stopped
temporarily while low dose corticosteroid being contin-
ued. After one week his dyspnoea and general condition
improved.
Discussion
Thalidomide was first approved in 1992 for treatment of
ENL by the Federal Drug Authority and its availability has
led to its therapeutic use and approval for multiple mye-
loma, as well as its off-label use in several other diseases
such as crohn’s disease, lupus erythematosus, and solid
organ malignancies of kidney, brain and breast. The exact
mechanism of action of thalidomide remains incompletely
defined and likely differs depending on the clinical entity
treated. It appears to have several immunomodulatory
properties, including suppression of TNF-[alpha] produc-
tion, down-regulation of cell-surface adhesion molecules
involved in leukocyte migration, decreasing circulating
helper T cell to suppressor T-cell ratio, and inhibition of
IFN-[alpha], all of which may play a role in the treatment
of ENL. [4] While teratogenicity and peripheral neuropa-
thy are the side effects of thalidomide that have attracted
the most attention, an emerging, relatively unrecognized
complication, as reported in this case is its thrombogenic
potential in particular following concurrent use with corti-
costeroids. Thrombocytopenia is also a recognized side
effect of thalidomide therapy as noted in our patient.
Majority of data on thalidomide and thromboembo-
lism currently comes in the cancer setting, particularly
Figure 1 Shows pitting oedema of right leg.
Ahamed et al. Thrombosis Journal 2011, 9:2
http://www.thrombosisjournal.com/content/9/1/2
Page 2 of 4in multiple myeloma, and particularly in combination
with chemotherapeutic agents. [1] The potential for
thrombotic events in ENL, specifically, and in the non-
cancer setting, in general, remains undefined. Nonethe-
less, there have been at least 15 cases of thromboses
reported in the literature occurring with thalidomide in
the non-cancer setting.
The Research on Adverse Drug events And Reports
(RADAR) project identified 695 reported cases of venous
thromboembolism (VTE) between 1998 and 2006 among
cancer patients on treatment that include chemotherapy
and/or dexamethasone with thalidomide. [5] In 2006, a
black box warning was added to the package insert for
thalidomide, indicating that patients with multiple mye-
loma who receive thalidomide-dexamethosone may bene-
fit from concurrent prophylaxis for thromboembolism. In
2007, guidelines were issued for VTE prophylaxis and
treatment in patients with cancer by the American
Society of Clinical Oncology. It is currently recom-
mended that patients receiving thalidomide with che-
motherapy or dexamethasone receive VTE prophylaxis
with low molecular weight heparin or warfarin. [6]
Conclusion
Presently, there are no guidelines on the optimal
antithrombotic prophylaxis in the non-cancer clinical
setting for the use of thalidomide. Although the pro-
thrombotic action of thalidomide in the cancer setting
has been accepted, there seems to be a similar and
well documented risk in the non-cancer setting as well,
which could lead to life-threatening complications such
as in our patient. The potential thrombotic risk in the
non-cancer setting of thalidomide should be empha-
sized due to following reasons; oral corticosteroids
being commonly used in dermatological and various
non-cancer conditions; reports of thromboembolic
events appear to be spontaneous and symptomatic; and
the majority of thromboembolic events develop shortly
after initiation of therapy, most within the first eight
weeks as in our patient. The potential risks in the off-
label use of thalidomide in the non-cancer setting
should be emphasized and extrapolating from studies
done in multiple myeloma, the use of antithrombotic
prophylaxis may be effective when thalidomide is used
in settings such as ENL.
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